[go: up one dir, main page]

NO994850L - Farmakologiske midler - Google Patents

Farmakologiske midler

Info

Publication number
NO994850L
NO994850L NO994850A NO994850A NO994850L NO 994850 L NO994850 L NO 994850L NO 994850 A NO994850 A NO 994850A NO 994850 A NO994850 A NO 994850A NO 994850 L NO994850 L NO 994850L
Authority
NO
Norway
Prior art keywords
pharmacological agents
glurs
selective
antagonists
receptor
Prior art date
Application number
NO994850A
Other languages
English (en)
Other versions
NO994850D0 (no
Inventor
David Bleakman
David R Helton
David Lodge
Smriti Iyengar
Paul L Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994850D0 publication Critical patent/NO994850D0/no
Publication of NO994850L publication Critical patent/NO994850L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Antagonister som er selektive for GluRS-reseptoren er brukbar for behandling av smerte. Også oppdaget er nye dekahydroisoquinolinderivater, som er selektive GluRS-reseptor- antagonister.
NO994850A 1997-04-07 1999-10-05 Farmakologiske midler NO994850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07
PCT/US1998/006905 WO1998045270A1 (en) 1997-04-07 1998-04-06 Pharmacological agents

Publications (2)

Publication Number Publication Date
NO994850D0 NO994850D0 (no) 1999-10-05
NO994850L true NO994850L (no) 1999-10-05

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994850A NO994850L (no) 1997-04-07 1999-10-05 Farmakologiske midler

Country Status (17)

Country Link
US (1) US6242462B1 (no)
EP (1) EP0980358A4 (no)
JP (1) JP2001521505A (no)
KR (1) KR20010006075A (no)
CN (1) CN1259126A (no)
AU (1) AU734657B2 (no)
BR (1) BR9809071A (no)
CA (1) CA2285192A1 (no)
EA (1) EA199900912A1 (no)
HU (1) HUP0002030A3 (no)
ID (1) ID23013A (no)
IL (1) IL132086A0 (no)
NO (1) NO994850L (no)
NZ (1) NZ337827A (no)
PL (1) PL336068A1 (no)
TR (1) TR199902449T2 (no)
WO (1) WO1998045270A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3209A1 (fr) 1999-07-06 2001-01-11 Lilly Co Eli Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
AU5591900A (en) 1999-07-06 2001-01-22 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
US6579886B2 (en) 1999-12-22 2003-06-17 Eli Lilly And Company Selective iglur5 receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
EP1351952A2 (en) 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
WO2002053555A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7488756B2 (en) 2001-01-23 2009-02-10 Neurosearch A/S Use of non-competitive and selective GluR5 antagonists as glutamate receptor modulating compounds
WO2003091243A1 (en) 2002-04-26 2003-11-06 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
WO2005007106A2 (en) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
CA2580730C (en) * 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
WO2008088820A2 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Glutamate receptor antagonists and methods of use
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor

Also Published As

Publication number Publication date
WO1998045270A1 (en) 1998-10-15
AU6955598A (en) 1998-10-30
CN1259126A (zh) 2000-07-05
AU734657B2 (en) 2001-06-21
TR199902449T2 (xx) 2000-07-21
KR20010006075A (ko) 2001-01-15
HUP0002030A3 (en) 2002-01-28
EA199900912A1 (ru) 2000-04-24
NO994850D0 (no) 1999-10-05
HUP0002030A2 (hu) 2001-04-28
BR9809071A (pt) 2000-08-01
ID23013A (id) 1999-12-30
PL336068A1 (en) 2000-06-05
EP0980358A4 (en) 2001-02-07
NZ337827A (en) 2000-12-22
EP0980358A1 (en) 2000-02-23
JP2001521505A (ja) 2001-11-06
CA2285192A1 (en) 1998-10-15
IL132086A0 (en) 2001-03-19
US6242462B1 (en) 2001-06-05

Similar Documents

Publication Publication Date Title
NO994850L (no) Farmakologiske midler
DK1208095T3 (da) Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
DK0806952T3 (da) Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
NO983002L (no) Vitronectin-reseptor-antagonister
NO20032360D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
NO20034122L (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
NO985225D0 (no) Indolderivater nyttige som endotelinreseptorantagonister
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO993350L (no) Vitronectin-reseptor-antagonister
TR200002896T2 (tr) Kalsilitik Bileşimler
DE60003899D1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
TR199700956T1 (xx) Indazolkarboksamidler.
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
EE9700309A (et) AII-retseptori antagonistide uus farmakoloogiline kasutus
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application